Leukemia clinical trials
The registry lists 5,446 studies for Leukemia across more than 10 countries. 639 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 2,898
- Terminated
- 833
- Status unknown
- 632
- Recruiting
- 497
- Withdrawn
- 254
- Active, not recruiting
- 147
Phase
- Phase 2
- 2,405
- Phase 1
- 1,871
- Phase 3
- 518
- Phase 4
- 109
- Early Phase 1
- 83
Where
- United States
- 3,019
- China
- 595
- France
- 489
- Germany
- 442
- Italy
- 423
- Canada
- 390
Who runs them
M.D. Anderson Cancer Center (299) · National Cancer Institute (NCI) (267) · Fred Hutchinson Cancer Center (138) · Children's Oncology Group (135) · Novartis Pharmaceuticals (108) · Memorial Sloan Kettering Cancer Center (80) · Gruppo Italiano Malattie EMatologiche dell'Adulto (66) · Masonic Cancer Center, University of Minnesota (60)
Studies
Recruiting first, then most recently updated. Showing 50 of 5,446 — search for more.
- Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT073285161 country
- Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT033421443 countries
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 21 country
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT037023091 country
- Rutgers University Study of the Genetics of Blood CancersRecruitingNCT077140441 country
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 215 countries
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 21 country
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaRecruitingNCT07504458Phase 35 countries
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT032267041 country
- Natural History Study of GATA2 Deficiency and Related DisordersRecruitingNCT019058261 country
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT009235071 country
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 11 country
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingNCT04065399Phase 1/211 countries
- Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingNCT06824168Phase 25 countries
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 214 countries
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk LeukemiaRecruitingNCT06810583Phase 11 country
- MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2RecruitingNCT05691608Not applicable1 country
- A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesRecruitingNCT06229912Phase 21 country
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta TestingRecruitingNCT06907797Not applicable1 country
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 35 countries
- RAT-HEMATO : Return to Work After Malignant HemopathyRecruitingNCT06262789Not applicable1 country
- Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and Parents' Bio-Psycho-Social and Spiritual HealthRecruitingNCT07805096Not applicable1 country
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 21 country
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationRecruitingNCT07249346Phase 21 country
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 213 countries
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesRecruitingNCT06408194Phase 11 country
- First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.RecruitingNCT07586618Phase 11 country
- Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyRecruitingNCT052379861 country
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 11 country
- Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT07284433Phase 1/22 countries
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 11 country
- Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaRecruitingNCT07439211Phase 11 country
- A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 11 country
- Musculoskeletal Ultrasound in Patients With Hematologic MalignanciesNot yet recruitingNCT07785505
- Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell TransplantationRecruitingNCT07573111Phase 11 country
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingNCT07007312Phase 316 countries
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06001788Phase 13 countries
- ADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin LymphomaEnrolling by invitationNCT052356331 country
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingNCT06137118Phase 1/213 countries
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingNCT05082519Phase 21 country
- Improving Cognitive Function in Older Adults Undergoing Stem Cell TransplantRecruitingNCT04898790Not applicable1 country
- Efficacy of Seated Exercise on Functional Capacity and Quality of Life in Patients With Leukemia During Chemotherapy CyclesNot yet recruitingNCT07740174Not applicable
- ALL Backbone in AYAsRecruitingNCT07227584Phase 21 country
- DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable1 country
- A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingNCT039111288 countries
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingNCT04307576Phase 315 countries
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 11 country
- Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic MalignanciesRecruitingNCT036806771 country
- Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ MalignanciesRecruitingNCT05391490Phase 11 country